-
1
-
-
85049057147
-
Character of terminal illness in the advanced cancer patient: Pain and other symptoms during the last four weeks of life
-
DOI 10.1016/S0885-3924(05)80021-1
-
Coyle N, Adelhardt J, Foley KM, et al. Character of terminal illness in the advanced cancer patient: pain and other symptoms during the last four weeks of life. J Pain Symptom Manage 1990;5:83-93 (Pubitemid 20241600)
-
(1990)
Journal of Pain and Symptom Management
, vol.5
, Issue.2
, pp. 83-93
-
-
Coyle, N.1
Adelhardt, J.2
Foley, K.M.3
Portenoy, R.K.4
-
3
-
-
0020586065
-
Steady-state kinetics and analgesic effect of oral morphine in cancer patients
-
Sawe J, Dahlstrom B, Rane A. Steady-state kinetics and analgesic effect of oral morphine in cancer patients. Eur J Clin Pharmacol 1983;24:537-42 (Pubitemid 13113590)
-
(1983)
European Journal of Clinical Pharmacology
, vol.24
, Issue.4
, pp. 537-542
-
-
Sawe, J.1
Dahlstrom, B.2
Rane, A.3
-
4
-
-
0343580459
-
Comparison of a once-a-day sustained-release morphine formulation with standard oral morphine treatment for cancer pain
-
DOI 10.1016/S0885-3924(97)00012-2, PII S0885392497000122
-
Broomhead A, Kerr R, Tester W, et al. Comparison of a once-a-day sustained-release morphine formulation with standard oral morphine treatment for cancer pain. J Pain Symptom Manage 1997;14:63-73 (Pubitemid 27323494)
-
(1997)
Journal of Pain and Symptom Management
, vol.14
, Issue.2
, pp. 63-73
-
-
Broomhead, A.1
Kerr, R.2
Tester, W.3
O'Meara, P.4
Maccarrone, C.5
Bowles, R.6
Hodsman, P.7
Smith, K.8
-
6
-
-
0027388896
-
Transdermal fentanyl for cancer pain: Repeated dose pharmacokinetics
-
Portenoy RK, Southam MA, Gupta SK, et al. Transdermal fentanyl for cancer pain. Repeated dose pharmacokinetics. Anesthesiology 1993;78:36-43 (Pubitemid 23038976)
-
(1993)
Anesthesiology
, vol.78
, Issue.1
, pp. 36-43
-
-
Portenoy, R.K.1
Southam, M.A.2
Gupta, S.K.3
Lapin, J.4
Layman, M.5
Inturrisi, C.E.6
Foley, K.M.7
-
7
-
-
0031056835
-
Transdermal fentanyl in the long-term treatment of cancer pain: A prospective study of 50 patients with advanced cancer of the gastrointestinal tract or the head and neck region
-
DOI 10.1016/S0304-3959(96)03254-X, PII S030439599603254X
-
Grond S, Zech D, Lehmann KA, et al. Transdermal fentanyl in the long-term treatment of cancer pain: a prospective study of 50 patients with advanced cancer of the gastrointestinal tract or the head and neck region. Pain 1997;69:191-8 (Pubitemid 27081425)
-
(1997)
Pain
, vol.69
, Issue.1-2
, pp. 191-198
-
-
Grond, S.1
Zech, D.2
Lehmann, K.A.3
Radbruch, L.4
Breitenbach, H.5
Hertel, D.6
-
8
-
-
0020508539
-
Clinical pharmacokinetics of fentanyl and its newer derivatives
-
Mather LE. Clinical pharmacokinetics of fentanyl and its newer derivatives. Clin Pharmacokinet 1983;8:422-46 (Pubitemid 13009122)
-
(1983)
Clinical Pharmacokinetics
, vol.8
, Issue.5
, pp. 422-446
-
-
Mather, L.E.1
-
9
-
-
0019965143
-
Plasma protein binding and distribution of fentanyl, sufentanil, alfentanil and lofentanil in blood
-
Meuldermans WE, Hurkmans RM, Heykants JJ. Plasma protein binding and distribution of fentanyl, sufentanil, alfentanil and lofentanil in blood. Arch Int Pharmacodyn Ther 1982;257:4-19 (Pubitemid 12071181)
-
(1982)
Archives Internationales de Pharmacodynamie et de Therapie
, vol.257
, Issue.1
, pp. 4-19
-
-
Meuldermans, W.E.G.1
Hurkmans, R.M.A.2
Heykants, J.J.P.3
-
10
-
-
0025336568
-
Breakthrough pain: Definition, prevalence and characteristics
-
DOI 10.1016/0304-3959(90)90004-W
-
Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990;41:273-81 (Pubitemid 20187930)
-
(1990)
Pain
, vol.41
, Issue.3
, pp. 273-281
-
-
Portenoy, R.K.1
Hagen, N.A.2
-
11
-
-
0032981296
-
Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: A controlled dose titration study
-
DOI 10.1016/S0304-3959(98)00179-1, PII S0304395998001791
-
Portenoy RK, Payne R, Coluzzi P, et al. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain 1999;79:303-12 (Pubitemid 29076765)
-
(1999)
Pain
, vol.79
, Issue.2-3
, pp. 303-312
-
-
Portenoy, R.K.1
Payne, R.2
Coluzzi, P.3
Raschko, J.W.4
Lyss, A.5
Busch, M.A.6
Frigerio, V.7
Ingham, J.8
Loseth, D.B.9
Nordbrock, E.10
Rhiner, M.11
-
12
-
-
0037221709
-
Cancer breakthrough pain characteristics and responses to treatment at a VA medical center
-
DOI 10.1016/S0304-3959(02)00293-2
-
Hwang SS, Chang VT, Kasimis B. Cancer breakthrough pain characteristics and responses to treatment at a VA medical center. Pain 2003;101:55-64 (Pubitemid 36044654)
-
(2003)
Pain
, vol.101
, Issue.1-2
, pp. 55-64
-
-
Hwang, S.S.1
Chang, V.T.2
Kasimis, B.3
-
13
-
-
0037758126
-
Morphine and alternative opioids in cancer pain: The EAPC recommendations
-
DOI 10.1054/bjoc.2001.1680
-
Hanks GW, Conno F, Cherny N, et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 2001;84:587-93 (Pubitemid 32238990)
-
(2001)
British Journal of Cancer
, vol.84
, Issue.5
, pp. 587-593
-
-
Hanks, G.W.1
De Conno, F.2
Cherny, N.3
Hanna, M.4
Kalso, E.5
McQuay, H.J.6
Mercadante, S.7
Meynadier, J.8
Poulain, P.9
Ripamonti, C.10
Radbruch, L.11
Casas, J.R.I.12
Sawe, J.13
Twycross, R.G.14
Ventafridda, V.15
-
14
-
-
33847772352
-
Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: An overview of its pharmacological and clinical characteristics
-
Mystakidou K, Katsouda E, Parpa E, et al. Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: an overview of its pharmacological and clinical characteristics. J Opioid Manag 2005;1:36-40
-
(2005)
J Opioid Manag
, vol.1
, pp. 36-40
-
-
Mystakidou, K.1
Katsouda, E.2
Parpa, E.3
-
15
-
-
0035059131
-
Breakthrough cancer pain: A randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR)
-
DOI 10.1016/S0304-3959(00)00427-9, PII S0304395900004279
-
Coluzzi PH, Schwartzberg L, Conroy JD, et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain 2001;91:123-30 (Pubitemid 32274181)
-
(2001)
Pain
, vol.91
, Issue.1-2
, pp. 123-130
-
-
Coluzzi, P.H.1
Schwartzberg, L.2
Conroy Jr., J.D.3
Charapata, S.4
Gay, M.5
Busch, M.A.6
Chavez, J.7
Ashley, J.8
Lebo, D.9
McCracken, M.10
Portenoy, R.K.11
-
16
-
-
70249110875
-
Oral transmucosal fentanyl citrate in cancer pain management: A practical application of nanotechnology
-
DOI 10.2147/nano.2007.2.1.49
-
Mystakidou K, Tsilika E, Tsiatas M, et al. Oral transmucosal fentanyl citrate in cancer pain management: a practical application of nanotechnology. Int J Nanomed 2007;2:49-54 (Pubitemid 46901781)
-
(2007)
International Journal of Nanomedicine
, vol.2
, Issue.1
, pp. 49-54
-
-
Mystakidou, K.1
Tsilika, E.2
Tsiatas, M.3
Vlahos, L.4
-
17
-
-
40849106512
-
Fentanyl buccal tablet
-
DOI 10.1358/dot.2008.44.1.1178469
-
Messina J, Darwish M, Fine PG. Fentanyl buccal tablet. Drugs Today (Barc) 2008;44:41-54 (Pubitemid 351397412)
-
(2008)
Drugs of Today
, vol.44
, Issue.1
, pp. 41-54
-
-
Messina, J.1
Darwish, M.2
Fine, P.G.3
-
18
-
-
72549117859
-
Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain
-
Rauck RL, Tark M, Reyes E, et al. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Curr Med Res Opin 2009;25:2877-85
-
(2009)
Curr Med Res Opin
, vol.25
, pp. 2877-85
-
-
Rauck, R.L.1
Tark, M.2
Reyes, E.3
-
19
-
-
33746849278
-
Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1080 pg versus Oral transmucosal fentanyl citrate 1600 pg and dose proportionality of FEBT 270 to 1300 g: A single-dose, randomized, open-label, three-period study in healthy adult volunteers
-
DOI 10.1016/j.clinthera.2006.05.016, PII S0149291806001275
-
Darwish M, Tempero K, Kirby M, et al. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers. Clin Ther 2006;28:715-24 (Pubitemid 44173055)
-
(2006)
Clinical Therapeutics
, vol.28
, Issue.5
, pp. 715-724
-
-
Darwish, M.1
Tempero, K.2
Kirby, M.3
Thompson, J.4
-
20
-
-
0032956343
-
A review of the use of fentanyl analgesia in the management of acute pain in adults
-
DOI 10.1097/00000542-199902000-00034
-
Peng PW, Sandler AN. A review of the use of fentanyl analgesia in the management of acute pain in adults. Anesthesiology 1999;90:576-99 (Pubitemid 29071528)
-
(1999)
Anesthesiology
, vol.90
, Issue.2
, pp. 576-599
-
-
Peng, P.W.H.1
Sandler, A.N.2
-
21
-
-
0028597470
-
The nasal route of cerebrospinal fluid drainage in man. A light-microscope study
-
Lowhagen P, Johansson BB, Nordborg C. The nasal route of cerebrospinal fluid drainage in man. A light-microscope study. Neuropathol Appl Neurobiol 1994;20:543-50
-
(1994)
Neuropathol Appl Neurobiol
, vol.20
, pp. 543-50
-
-
Lowhagen, P.1
Johansson, B.B.2
Nordborg, C.3
-
22
-
-
18444363020
-
Nasal administration of opioids for pain management in adults
-
DOI 10.1034/j.1399-6576.2002.460702.x
-
Dale O, Hjortkjaer R, Kharasch ED. Nasal administration of opioids for pain management in adults. Acta Anaesthesiol Scand 2002;46:759-70 (Pubitemid 34803193)
-
(2002)
Acta Anaesthesiologica Scandinavica
, vol.46
, Issue.7
, pp. 759-770
-
-
Dale, O.1
Hjortkjaer, R.2
Kharasch, E.D.3
-
23
-
-
51249162526
-
Pharmacokinetics of intranasal fentanyl
-
Striebel HW, Kramer J, Luhmann I, et al. Pharmacokinetics of intranasal fentanyl. Schmerz 1993;7:122-5
-
(1993)
Schmerz
, vol.7
, pp. 122-5
-
-
Striebel, H.W.1
Kramer, J.2
Luhmann, I.3
-
24
-
-
41649083735
-
Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: A randomized, double-blind, double-dummy, two-way, crossover study
-
DOI 10.1016/j.clinthera.2008.03.001, PII S0149291808001021
-
Christrup LL, Foster D, Popper LD, et al. Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: a randomized, double-blind, double-dummy, two-way, crossover study. Clin Ther 2008;30:469-81 (Pubitemid 351483922)
-
(2008)
Clinical Therapeutics
, vol.30
, Issue.3
, pp. 469-481
-
-
Christrup, L.L.1
Foster, D.2
Popper, L.D.3
Troen, T.4
Upton, R.5
-
25
-
-
41049094950
-
Early pharmacokinetics of nasal fentanyl: Is there a significant arterio-venous difference?
-
Moksnes K, Fredheim OM, Klepstad P, et al. Early pharmacokinetics of nasal fentanyl: is there a significant arterio-venous difference? Eur J Clin Pharmacol 2008;64:497-502
-
(2008)
Eur J Clin Pharmacol
, vol.64
, pp. 497-502
-
-
Moksnes, K.1
Fredheim, O.M.2
Klepstad, P.3
-
26
-
-
77949504066
-
Pharmacokinetics of intranasal fentanyl spray in patients with cancer and breakthrough pain
-
Kaasa S, Moksnes K, Nolte T, et al. Pharmacokinetics of intranasal fentanyl spray in patients with cancer and breakthrough pain. J Opioid Manag 2010;6:17-26
-
(2010)
J Opioid Manag
, vol.6
, pp. 17-26
-
-
Kaasa, S.1
Moksnes, K.2
Nolte, T.3
-
27
-
-
77955260161
-
Pharmacokinetics, analgesic effect, and tolerability of a single preprocedural dose of intranasal fentanyl in patients undergoing drain removal after breast reduction or augmentation surgery: A prospective, randomized, double-blind, placebo-controlled study
-
Veldhorst-Janssen NM, Fiddelers AA, van der Kuy PH, et al. Pharmacokinetics, analgesic effect, and tolerability of a single preprocedural dose of intranasal fentanyl in patients undergoing drain removal after breast reduction or augmentation surgery: a prospective, randomized, double-blind, placebo-controlled study. Clin Ther 2010;32:1427-36
-
(2010)
Clin Ther
, vol.32
, pp. 1427-36
-
-
Veldhorst-Janssen, N.M.1
Fiddelers, A.A.2
Van Der Kuy, P.H.3
-
28
-
-
76749095006
-
Pharmacokinetic comparisons of three nasal fentanyl formulations; Pectin, chitosan and chitosan-poloxamer 188
-
Fisher A, Watling M, Smith A, et al. Pharmacokinetic comparisons of three nasal fentanyl formulations; pectin, chitosan and chitosan-poloxamer 188. Int J Clin Pharmacol Ther 2010;48:138-45
-
(2010)
Int J Clin Pharmacol Ther
, vol.48
, pp. 138-45
-
-
Fisher, A.1
Watling, M.2
Smith, A.3
-
29
-
-
78650820821
-
Pharmacokinetics and relative bioavailability of fentanyl pectin nasal spray 100 - 800 g in healthy volunteers
-
Fisher A, Watling M, Smith A, et al. Pharmacokinetics and relative bioavailability of fentanyl pectin nasal spray 100 - 800 g in healthy volunteers. Int J Clin Pharmacol Ther 2010;48:860-7
-
(2010)
Int J Clin Pharmacol Ther
, vol.48
, pp. 860-7
-
-
Fisher, A.1
Watling, M.2
Smith, A.3
-
30
-
-
0033797308
-
An assessment of the safety, efficacy, and acceptability of intranasal fentanyl citrate in the management of cancer-related breakthrough pain: A pilot study
-
Zeppetella G. An assessment of the safety, efficacy, and acceptability of intranasal fentanyl citrate in the management of cancer-related breakthrough pain: a pilot study. J Pain Symptom Manage 2000;20:253-8
-
(2000)
J Pain Symptom Manage
, vol.20
, pp. 253-8
-
-
Zeppetella, G.1
-
31
-
-
68949120909
-
Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: A phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period
-
Kress HG, Oronska A, Kaczmarek Z, et al. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period. Clin Ther 2009;31:1177-91
-
(2009)
Clin Ther
, vol.31
, pp. 1177-91
-
-
Kress, H.G.1
Oronska, A.2
Kaczmarek, Z.3
-
32
-
-
72549097280
-
A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: An open-label, randomised, crossover trial
-
Mercadante S, Radbruch L, Davies A, et al. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial. Curr Med Res Opin 2009;25:2805-15
-
(2009)
Curr Med Res Opin
, vol.25
, pp. 2805-15
-
-
Mercadante, S.1
Radbruch, L.2
Davies, A.3
-
33
-
-
77956098539
-
Fentanyl pectin nasal spray in breakthrough cancer pain
-
Taylor D, Galan V, Weinstein SM, et al. Fentanyl pectin nasal spray in breakthrough cancer pain. J Support Oncol 2010;8:184-90
-
(2010)
J Support Oncol
, vol.8
, pp. 184-90
-
-
Taylor, D.1
Galan, V.2
Weinstein, S.M.3
-
34
-
-
78049464453
-
A multicenter, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain
-
Portenoy RK, Burton AW, Gabrail N, et al. A multicenter, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain. Pain 2010;151:617-24
-
(2010)
Pain
, vol.151
, pp. 617-24
-
-
Portenoy, R.K.1
Burton, A.W.2
Gabrail, N.3
-
35
-
-
78349255209
-
Efficacy, safety and patient acceptability of fentanyl pectin nasal spray compared with immediate-release morphine sulphate tablets in the treatment of breakthrough cancer pain: A multi-center, double-blind, double-dummy, multiple-crossover study
-
Fallon M, Gatti A, Davies A, et al. Efficacy, safety and patient acceptability of fentanyl pectin nasal spray compared with immediate-release morphine sulphate tablets in the treatment of breakthrough cancer pain: a multi-center, double-blind, double-dummy, multiple-crossover study. Eur J Cancer Supp 2009;7:15
-
(2009)
Eur J Cancer Supp
, vol.7
, pp. 15
-
-
Fallon, M.1
Gatti, A.2
Davies, A.3
-
36
-
-
79951877274
-
Consistency of efficacy, patient acceptability, and nasal tolerability of fentanyl pectin nasal spray compared with immediate-release morphine sulfate in breakthrough cancer pain
-
Davies A, Sitte T, Elsner F, et al. Consistency of efficacy, patient acceptability, and nasal tolerability of fentanyl pectin nasal spray compared with immediate-release morphine sulfate in breakthrough cancer pain. J Pain Symptom Manage 2011;41:358-66
-
(2011)
J Pain Symptom Manage
, vol.41
, pp. 358-66
-
-
Davies, A.1
Sitte, T.2
Elsner, F.3
-
37
-
-
78349255839
-
Long-term safety, tolerability, and consistency of effect of fentanyl pectin nasal spray for breakthrough cancer pain in opioid-tolerant patients
-
Portenoy RK, Raffaeli W, Torres LM, et al. Long-term safety, tolerability, and consistency of effect of fentanyl pectin nasal spray for breakthrough cancer pain in opioid-tolerant patients. J Opioid Manag 2010;6:319-28
-
(2010)
J Opioid Manag
, vol.6
, pp. 319-28
-
-
Portenoy, R.K.1
Raffaeli, W.2
Torres, L.M.3
|